Skip to content
10-Q

Quarterly Report

Jade Biosciences, Inc. JBIO

0001193125-26-212088

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 49.36M sh
Shares Diluted Q1 2026 · Mar 31, 2026 57.78M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 3.16M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$24.08M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$18.76M
Short Term Investments Q1 2026 · Mar 31, 2026 $256.21M
Short Term Investments Q1 2026 · Dec 31, 2025 $247.72M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $55.09M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $88.44M
Stockholders Equity Q1 2026 · Mar 31, 2026 $296.46M
Stockholders Equity Q1 2026 · Dec 31, 2025 $332.52M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 −$83.51M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 −$46.8M
Current Liabilities Q1 2026 · Mar 31, 2026 $22.29M
Current Liabilities Q1 2026 · Dec 31, 2025 $16.54M
Total Liabilities Q1 2026 · Mar 31, 2026 $22.97M
Total Liabilities Q1 2026 · Dec 31, 2025 $17.26M
Current Assets Q1 2026 · Mar 31, 2026 $318.52M
Current Assets Q1 2026 · Dec 31, 2025 $348.82M
Total Assets Q1 2026 · Mar 31, 2026 $319.43M
Total Assets Q1 2026 · Dec 31, 2025 $349.78M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.57
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$12.10
Eps Basic Q1 2026 · Mar 31, 2026 −$0.57
Eps Basic restated Q1 2026 · Mar 31, 2025 −$12.10
Sga Expense Q1 2026 · Mar 31, 2026 $7.39M
Sga Expense restated Q1 2026 · Mar 31, 2025 $3.36M
Rd Expense Q1 2026 · Mar 31, 2026 $36.05M
Rd Expense Q1 2026 · Mar 31, 2025 $20.02M
Net Income Q1 2026 · Mar 31, 2026 −$40.37M
Net Income restated Q1 2026 · Mar 31, 2025 −$38.17M
Operating Income Q1 2026 · Mar 31, 2026 −$43.45M
Operating Income restated Q1 2026 · Mar 31, 2025 −$23.38M